GlassScriptPhysician profile
Michael Porubcin
NPI 1770553349
$20,483.96
in general payments reported to CMS, 2019-2025
56 companies · $4,001 in 2025
The $4,001 reported for 2025 was more than what 79% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,296 · 2020: $1,788 · 2021: $2,760 · 2022: $901 · 2023: $913 · 2024: $4,825 · 2025: $4,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,710 · Consulting Fee: $1,838 · Education: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,710.13 |
| Consulting Fee | $1,837.50 |
| Education | $191.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $6,523.97 | 2019-2025 | Kisqali |
| Glaxosmithkline, LLC. | $1,896.00 | 2021-2025 | Ojjaara, Jemperli, Zejula |
| Eisai INC. | $1,590.57 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,126.99 | 2019-2025 | Tagrisso, Imfinzi, Enhertu |
| Janssen Biotech, INC. | $1,024.72 | 2019-2025 | Erleada, Akeega, Darzalex |
| Daiichi Sankyo INC. | $797.74 | 2019-2025 | Datroway, Enhertu, Vanflyta |
| Genzyme Corporation | $585.50 | 2019-2025 | |
| Genentech USA, INC. | $534.59 | 2019-2025 | Venclexta, Polivy, Tecentriq |
| Beigene, LTD. | $525.00 | 2021 | |
| Abbvie INC. | $484.03 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $434.86 | 2019-2025 | Opdivo, Opdualag, Augtyro |
| Myriad Genetic Laboratories, INC. | $360.79 | 2023-2024 | Myrisk |
| Merck Sharp & Dohme LLC | $340.26 | 2019-2025 | Keytruda, Welireg, Reblozyl |
| Astellas Pharma US INC | $308.24 | 2024-2025 | Vyloy, Padcev, Xospata |
| Seagen INC. | $281.28 | 2021-2025 | Padcev, Adcetris |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $258.47 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $254.40 | 2024-2025 | Libtayo, Lynozyfic |
| Lilly USA, LLC | $252.60 | 2019-2025 | Verzenio, Jaypirca |
| Jazz Pharmaceuticals INC. | $246.69 | 2022-2025 | Zepzelca |
| Takeda Pharmaceuticals U.S.A., INC. | $223.61 | 2019-2025 | Hyqvia, Alunbrig |
| Stemline Therapeutics INC. | $184.48 | 2023-2025 | Orserdu |
| Amgen INC. | $175.39 | 2019-2022 | |
| Mirati Therapeutics, INC. | $162.80 | 2023-2024 | Krazati |
| Genmab U.S., INC. | $153.82 | 2024-2025 | Epkinly |
| Celgene Corporation | $151.11 | 2023-2025 | Reblozyl |
| Servier Pharmaceuticals LLC | $135.54 | 2024-2025 | |
| Healthmyne, INC. | $132.24 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $121.38 | 2023-2025 | Tazverik, Onivyde |
| Beigene USA, INC. | $121.22 | 2023 | Brukinsa |
| Geron Corporation | $102.04 | 2024-2025 | Rytelo |
| Exelixis INC. | $100.02 | 2019-2025 | Cabometyx |
| Incyte Corporation | $98.50 | 2023-2025 | Jakafi |
| Recordati_rare_diseases_inc. | $87.89 | 2025 | Enjaymo |
| Bayer Healthcare Pharmaceuticals INC. | $83.18 | 2024-2025 | |
| Gilead Sciences, INC. | $63.64 | 2021-2025 | Trodelvy |
| Agios Pharmaceuticals, INC. | $51.93 | 2020-2025 | Pyrukynd |
| Alexion Pharmaceuticals, INC. | $50.92 | 2020-2024 | Ultomiris |
| Array Biopharma INC | $43.57 | 2019-2025 | Tukysa, Braftovi, Mektovi |
| Puma Biotechnology, INC. | $43.16 | 2020-2021 | |
| Pharmaessentia USA Corporation | $38.16 | 2024-2025 | Besremi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.24 | 2025 | |
| Sobi, INC | $32.50 | 2024 | |
| Beone Medicines USA, INC. | $24.82 | 2025 | Brukinsa |
| Karyopharm Therapeutics INC. | $23.80 | 2022 | |
| Mirum Pharmaceuticals, INC. | $23.07 | 2024 | Cholbam |
| Apellis Pharmaceuticals, INC. | $23.00 | 2022 | |
| Octapharma USA, INC. | $21.02 | 2024 | Octagam Immune Globulin (Human) |
| Syndax Pharmaceuticals, INC. | $20.14 | 2025 | |
| Adc Therapeutics America, INC. | $19.15 | 2025 | |
| Verastem, INC. | $19.09 | 2020 | |
| Tesaro, INC. | $17.25 | 2019 | |
| Taiho Oncology, INC. | $16.05 | 2025 | |
| Alnylam Pharmaceuticals INC. | $15.91 | 2024 | Givlaari |
| Deciphera Pharmaceuticals INC. | $15.26 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $14.95 | 2020 | |
| Rigel Pharmaceuticals, INC. | $12.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Porubcin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.